Abcam, ab323898, Alexa Fluor® 488 Anti-SFTPA1 + SFTPA2 antibody [EPR29098-6]

Size: 100µL
Rabbit Recombinant Monoclonal Pulmonary surfactant-associated protein A1 antibody - conjugated to Alexa Fluor® 488. Suitable for IHC-P and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR29098-6,
Isotype:IgG,
Conjugation:Alexa Fluor® 488,
Excitation/Emission:Ex: 495nm, Em: 519nm,
Carrier free:No,
Reacts with:Human,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The immunogen shares no sequence similarity with SFTPB, SFTPC or SFTPD. Based on the immunogen sequence, we do not expect this antibody to cross-react with SFTPB, SFTPC or SFTPD.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Preservative: 0.02% Sodium azideConstituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle, Store in the dark

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SFTPA1 and SFTPA2 also known as surfactant protein A1 and A2 are essential components of the pulmonary surfactant system. SFTPA1 and SFTPA2 are glycoproteins with a molecular mass of approximately 26 kDa. These proteins are mainly expressed in the lung alveolar type II epithelial cells. They play a critical role in reducing surface tension in the alveoli preventing lung collapse during respiration. SFTPA1 and SFTPA2 bind to lipids within the surfactant helping to maintain its structure and function.
Biological function summary
SFTPA1 and SFTPA2 are involved in the immune defense mechanisms of the lungs. Both proteins are part of the collectin family and form higher-order oligomeric structures. As a component of the surfactant protein complex they enhance phagocytosis of pathogens by alveolar macrophages and neutralize pathogens directly. Additionally they modulate inflammatory responses in the lung therefore contributing to the protection of pulmonary tissues.
Pathways
SFTPA1 and SFTPA2 are integral to the innate immune response and lipid metabolism pathways in the lungs. They interact with toll-like receptors (TLRs) and other surfactant proteins like surfactant protein D (SFTPD) to activate signaling pathways that lead to inflammation control. SFTPA1 and SFTPA2 also influence surfactant homeostasis within the lung environment contributing to the maintenance of respiratory function.
SFTPA1 and SFTPA2 relate closely to respiratory distress syndrome (RDS) and pulmonary alveolar proteinosis (PAP). Mutations in SFTPA1 and SFTPA2 genes can impair surfactant function which often results in RDS particularly in premature infants. Moreover alterations in these proteins can also contribute to PAP where abnormal surfactant accumulation occurs. Their interplay with proteins like surfactant protein B (SFTPB) further links them to these pulmonary disorders as these proteins work together to ensure proper surfactant functionality.